Absci and precisionlife announce strategic r&d partnership to jointly develop ai-enabled drug pipeline

Leading ai biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments with this partnership, absci achieves 2023 outlook of ten new active programs signed for the year vancouver, wash., dec. 20, 2023 (globe newswire) -- absci (nasdaq: absi), a generative ai drug creation company, and precisionlife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs.
ABSI Ratings Summary
ABSI Quant Ranking